Intervention

Acarbose (Glucobay, BAYG5421)

ClinicalTrials.gov intervention label

Clinical trials8

Recruiting0

Common conditions3

Lead sponsors shown1

Clinical trials

8 shown

Bioequivalence Study for Acarbose / Metformin FDCNCT01728740 · 2012-09-01

A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mgNCT01554631 · 2012-03-01

A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard TabletNCT01388153 · 2011-06-01

GlucoFriend-evaluation the Effectiveness of Glucobay When Combined With a Basal InsulinNCT01248481 · 2010-09-01

Glucose Reduction by Early Acarbose Treatment in Basal InsulinNCT00970528 · 2009-11-01

GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient GroupsNCT00909051 · 2009-03-24

Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular DiseaseNCT01167231 · 2007-05-01

Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary CareNCT01010100 · 2000-08-01

Common conditions

Diabetes Mellitus4 Diabetes Mellitus, Type 23 Diabetes Mellitus, Type II1

Leading sponsors

Trial status mix

COMPLETED8

Phase mix

PHASE13

PHASE31

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.